시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 고환 핵단백질 정중선암(NUT 정중선암) 치료 시장 보고서(2025년)
Nuclear Protein In Testis Midline Carcinoma Treatment Global Market Report 2025
상품코드 : 1889523
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,573,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,501,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,429,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

고환 핵단백질 정중선암(NUT 정중선암) 치료 시장 규모는 최근 급속히 확대되고 있습니다. 2024년의 195억 6,000만 달러에서 2025년에는 223억 달러로, CAGR 14.0%로 성장하였습니다. 지난 수년간의 성장은 희소 침공성 암에 대한 표적 요법 수요 증가, 종양학 조사에 대한 투자 확대, 면역요법 치료의 보급 확대, 임상시험 수 증가, 희소 침공성 암의 발생률 상승에 의해 발생했습니다.

고환 핵단백질 정중선암(NUT 정중선암) 치료 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 372억 1,000만 달러에 달하고, CAGR은 13.7%를 나타낼 전망입니다. 예측기간의 성장 요인으로는 맞춤 의료의 보급 확대, 희소암 연구에 대한 정부 자금 증가, 혁신적 치료법의 규제 승인 증가, 병용 치료에 대한 관심 고조, 기존 약제의 적응 외 사용 증가를 들 수 있습니다. 예측 기간 동안 예상되는 주요 동향은 분자진단 기술의 진보, BET 억제제 설계의 혁신, 병용 치료 연구의 발전, 후성적 치료의 진전, 동반자 진단 도구의 고도화가 있습니다.

암 연구에 대한 투자 증가는 향후 수년간 고환 핵단백질 정중선암(NUT 정중선암) 치료 시장의 성장을 가속할 것으로 예측됩니다. 암 연구에 대한 투자란 정부, 조직 또는 민간 단체가 암의 이해, 예방, 치료를 목적으로 한 연구, 임상시험, 혁신 기술에 자금을 공급하기 위해 할당하는 재정적 자원을 말합니다. 투자 증가는 암 이환율의 상승에 의해 추진되고 있으며, 보다 우수한 치료법과 혁신적 요법에 대한 긴급 필요성이 발생하고 있습니다. 이 투자는 표적요법, 진보된 진단기술, 신규 치료 접근법의 개발을 가능하게 함으로써 고환 핵단백질 정중선암 치료의 연구를 지원합니다. 예를 들어, 영국 미디어 기업 Civil Society Media사에 따르면, 2024년 9월 시점에서 영국 암 연구기구(Cancer Research UK)는 2023-2024년도에 17만 3,700달러의 자금을 조달하였으며, 이는 전년도의 1억 3,600만 달러에서 3,300만 달러 증가한 금액입니다. 따라서 암 연구에 대한 투자 증가가 고환 핵단백질 정중선암 치료 시장의 성장을 가속하고 있습니다.

또한 임상시험 증가도 고환 핵단백질 정중선암(NUT 정중선암) 치료 시장의 성장을 지지하고 있습니다. 임상시험이란 새로운 의료처치, 의약품, 개입법의 안전성, 유효성, 효과를 평가하기 위해 인간을 대상으로 신중하게 설계된 연구입니다. 임상시험 증가는 질병의 유병률 상승으로 인해 새롭고 효과적인 치료법이 긴급하게 요구되고 있기 때문입니다. 임상시험은 신규 요법의 안전성, 유효성, 최적 사용법을 평가함으로써 NUT 정중선암 치료를 진보시켜 표적 치료법의 개발을 가속화합니다. 예를 들어 영국에 본사를 둔 업계 단체인 영국제약공업협회(ABPI)에 따르면 2024년 12월 시점에서 영국에서 시작된 업계의 임상시험 총수는 2023년 426건에 달하였고, 2022년 411건에서 증가하여 2년 연속 성장을 기록했습니다. 따라서 임상시험 수 증가가 시장 성장을 견인할 전망입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장의 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Nuclear protein in testis (NUT) midline carcinoma treatment refers to medical interventions used to manage a rare, aggressive cancer defined by NUT gene rearrangements, typically occurring in midline structures such as the head, neck, and thorax. Treatment often involves a combination of surgery, chemotherapy, and emerging targeted therapies designed to inhibit the NUT fusion protein and limit tumor growth.

The main treatments for nuclear protein in testis midline carcinoma include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and other therapeutic approaches. Chemotherapy refers to the use of potent drugs that kill or inhibit the growth of cancer cells in the body. These treatments rely on various technologies, including molecular profiling, personalized medicine strategies, next-generation sequencing (NGS), and others, and are administered through oral, intravenous, or other delivery routes. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and direct sales channels and are utilized by end users such as hospitals, specialty cancer clinics, ambulatory surgical centers, cancer research institutes, academic hospitals, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The nuclear protein in testis midline carcinoma market research report is one of a series of new reports from The Business Research Company that provides nuclear protein in testis midline carcinoma market statistics, including nuclear protein in testis midline carcinoma industry global market size, regional shares, competitors with a nuclear protein in testis midline carcinoma market share, detailed nuclear protein in testis midline carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear protein in testis midline carcinoma industry. This nuclear protein in testis midline carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear protein in testis midline carcinoma treatment market size has grown rapidly in recent years. It will grow from $19.56 billion in 2024 to $22.30 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. Growth during the historic period can be attributed to increasing demand for targeted therapies for rare aggressive cancers, rising investment in oncology research, growing adoption of immunotherapy treatments, an expanding number of clinical trials, and a rising incidence of rare aggressive cancers.

The nuclear protein in testis midline carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $37.21 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. Growth in the forecast period can be attributed to the growing adoption of personalized medicine, increased government funding for rare cancer research, rising regulatory approval of innovative therapies, greater interest in combination treatments, and increasing off-label use of existing drugs. Major trends expected in the forecast period include technological advancements in molecular diagnostics, innovations in BET inhibitor drug design, developments in combination therapy research, progress in epigenetic therapeutics, and advancements in companion diagnostic tools.

The rising investment in cancer research is expected to drive the growth of the nuclear protein in testis midline carcinoma treatment market in the coming years. Investment in cancer research refers to the allocation of financial resources by governments, organizations, or private entities to fund studies, clinical trials, and innovations aimed at understanding, preventing, and treating cancer. Increased investment is driven by the rising prevalence of cancer, creating an urgent need for better treatments and innovative therapies. This investment supports nuclear protein in testis (NUT) midline carcinoma treatment by enabling the development of targeted therapies, advanced diagnostics, and novel treatment approaches. For example, in September 2024, according to Civil Society Media Limited, a UK-based media company, Cancer Research UK spent $0.0001737 billion on raising funds in 2023-2024, marking an increase of $0.0305 billion from the $0.136 billion spent the previous year. Therefore, rising investment in cancer research is fueling growth in the NUT midline carcinoma treatment market.

The growth of the nuclear protein in testis midline carcinoma treatment market is also supported by the increasing number of clinical trials. Clinical trials are carefully designed studies conducted with human participants to evaluate the safety, efficacy, and effectiveness of new medical treatments, drugs, or interventions. The rise in clinical trials is due to the increasing prevalence of diseases, creating a critical need for new and effective treatments. Clinical trials advance NUT midline carcinoma treatment by evaluating novel therapies' safety, efficacy, and optimal use, accelerating the development of targeted treatment options. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the total number of industry clinical trials initiated in the UK reached 426 in 2023, up from 411 in 2022, marking growth for the second consecutive year. Therefore, the increasing number of clinical trials is driving market growth.

Major companies in the NUT midline carcinoma treatment market are focusing on innovative combination therapies to enhance efficacy and improve patient outcomes. Combination therapies use two or more different drugs or approaches together to increase effectiveness and reduce resistance in treating disease. For example, in July 2025, Zenith Epigenetics Ltd., a Canada-based clinical-stage biotechnology company, received FDA Fast Track designation for ZEN 3694 in combination with abemaciclib to treat patients with metastatic or unresectable NUT carcinoma who have undergone at least one prior chemotherapy regimen. This designation aims to accelerate development and regulatory review for therapies addressing serious conditions with unmet medical needs. These therapies, including an oral BET inhibitor targeting the oncogenic NUTM1 fusion protein, combined with abemaciclib, a CDK4/6 inhibitor, help inhibit cancer cell proliferation and improve patient outcomes.

Major companies operating in the nuclear protein in testis midline carcinoma treatment market are Johnson And Johnson, F. Hoffmann-La Roche Limited, Merck & Company Inc., Pfizer Inc., AbbVie Incorporated, Novartis International AG, Bristol-Myers Squibb Company, GlaxoSmithKline Public Limited Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Siemens Healthineers AG, Biogen Inc., Illumina Inc., Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, ViewRay Inc., Arcus Biosciences Inc., Xilio Therapeutics Inc., Zenith Epigenetics Inc.

North America was the largest region in the nuclear protein in testis midline carcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nuclear protein in testis midline carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nuclear protein in testis midline carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear protein in testis midline carcinoma treatment market consists of revenues earned by entities by providing services such as pharmaceutical treatment services, intravenous administration services, molecular diagnostics and genetic profiling services, hospital and oncology clinic services, and clinical trial and orphan drug development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Protein In Testis Midline Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear protein in testis midline carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for nuclear protein in testis midline carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear protein in testis midline carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Nuclear Protein In Testis Midline Carcinoma Treatment Market Characteristics

3. Nuclear Protein In Testis Midline Carcinoma Treatment Market Trends And Strategies

4. Nuclear Protein In Testis Midline Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nuclear Protein In Testis Midline Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Nuclear Protein In Testis Midline Carcinoma Treatment Market Segmentation

7. Nuclear Protein In Testis Midline Carcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Nuclear Protein In Testis Midline Carcinoma Treatment Market

9. China Nuclear Protein In Testis Midline Carcinoma Treatment Market

10. India Nuclear Protein In Testis Midline Carcinoma Treatment Market

11. Japan Nuclear Protein In Testis Midline Carcinoma Treatment Market

12. Australia Nuclear Protein In Testis Midline Carcinoma Treatment Market

13. Indonesia Nuclear Protein In Testis Midline Carcinoma Treatment Market

14. South Korea Nuclear Protein In Testis Midline Carcinoma Treatment Market

15. Western Europe Nuclear Protein In Testis Midline Carcinoma Treatment Market

16. UK Nuclear Protein In Testis Midline Carcinoma Treatment Market

17. Germany Nuclear Protein In Testis Midline Carcinoma Treatment Market

18. France Nuclear Protein In Testis Midline Carcinoma Treatment Market

19. Italy Nuclear Protein In Testis Midline Carcinoma Treatment Market

20. Spain Nuclear Protein In Testis Midline Carcinoma Treatment Market

21. Eastern Europe Nuclear Protein In Testis Midline Carcinoma Treatment Market

22. Russia Nuclear Protein In Testis Midline Carcinoma Treatment Market

23. North America Nuclear Protein In Testis Midline Carcinoma Treatment Market

24. USA Nuclear Protein In Testis Midline Carcinoma Treatment Market

25. Canada Nuclear Protein In Testis Midline Carcinoma Treatment Market

26. South America Nuclear Protein In Testis Midline Carcinoma Treatment Market

27. Brazil Nuclear Protein In Testis Midline Carcinoma Treatment Market

28. Middle East Nuclear Protein In Testis Midline Carcinoma Treatment Market

29. Africa Nuclear Protein In Testis Midline Carcinoma Treatment Market

30. Nuclear Protein In Testis Midline Carcinoma Treatment Market Competitive Landscape And Company Profiles

31. Nuclear Protein In Testis Midline Carcinoma Treatment Market Other Major And Innovative Companies

32. Global Nuclear Protein In Testis Midline Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Protein In Testis Midline Carcinoma Treatment Market

34. Recent Developments In The Nuclear Protein In Testis Midline Carcinoma Treatment Market

35. Nuclear Protein In Testis Midline Carcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기